Key Insights

Highlights

Treatment Research

1 treatments under study, led by Slc1a5 Expression

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 50/100

Termination Rate

0.0%

0 terminated out of 1 trials

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 0 completed with results

Key Signals

Data Visualizations

Phase Distribution

Trial Status

Unknown1

Clinical Trials (1)

Showing 1 of 1 trials
NCT02633436Unknown

Research on the Role of SLC1A5 in the Development of Esophageal Cancer

Showing all 1 trials

Research Network

Common Treatments

  • Slc1a5 Expression1

Active Sponsors

  • Fourth Affiliated Hospital of Guangxi Medical University1
  • Liuzhou Maternity and Child Healthcare Hospital1

Top Investigators

Related Conditions

  • Esophageal Cancer1

Activity Timeline